The Drug Controller General of India (DCGI) has approved a game changing eye drop that promises to reduce reliance on reading glasses. Entod Pharmaceuticals, based in Mumbai, has announced the final approval for PresVu eye drops, with plans to introduce the product to the domestic market in the first week of October.
A Pioneering Treatment for Presbyopia
PresVu eye drops by Entod Pharmaceuticals mark a significant advancement in the treatment of presbyopia, a common age-related vision condition affecting individuals over 40. This approval follows a recommendation from the Subject Expert Committee (SEC) of the Central Drugs Standard Control Organisation (CDSCO). Traditionally managed with reading glasses, contact lenses, or surgical interventions, presbyopia can now be effectively treated with PresVu, which improves near vision within just 15 minutes, according to Dr. Aditya Sethi in an interview with NDTV.
Entod Pharmaceuticals: A Milestone in Eye Care
"This approval from the DCGI is a significant milestone in our mission to revolutionize eye care in India," stated Nikkhil K Masurkar, CEO of Entod Pharmaceuticals, as reported by PTI. "PresVu eye drops are more than just a product; they represent a solution that can enhance the lives of millions by providing greater visual independence."
Addressing a Global Vision Challenge
Presbyopia affects between 1.09 and 1.8 billion people worldwide, presenting a widespread challenge as individuals age and experience reduced ability to focus on nearby objects. Entod Pharmaceuticals aims to tackle this issue not only in India but also in emerging markets such as Africa and Southeast Asia.
Innovation and Global Strategy
Entod Pharmaceuticals is set to shift the focus from exporting low-cost generics to leading in innovation and becoming a global frontrunner in new developments. "We aim to change the landscape by focusing on innovation and out-licensing to other countries," Masurkar explained, outlining the company's future strategy.
PresVu eye drops represent a significant leap forward in eye care, offering a novel solution to a common problem and setting the stage for global expansion and innovation in the pharmaceutical industry.
